These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 25592211)
1. The double-edged sword of ADT: emerging evidence of cardiovascular, pulmonary, and renal risks. Anantharaman A; Friedlander TW Oncology (Williston Park); 2015 Jan; 29(1):67-8. PubMed ID: 25592211 [No Abstract] [Full Text] [Related]
2. ADT risks and side effects in advanced prostate cancer: cardiovascular and acute renal injury. Crawford ED; Moul JW Oncology (Williston Park); 2015 Jan; 29(1):55-8, 65-6. PubMed ID: 25592210 [TBL] [Abstract][Full Text] [Related]
3. Can exercise ameliorate the increased risk of cardiovascular disease and diabetes associated with ADT? Galvão DA; Newton RU; Taaffe DR; Spry N Nat Clin Pract Urol; 2008 Jun; 5(6):306-7. PubMed ID: 18431358 [No Abstract] [Full Text] [Related]
4. I'm on androgen deprivation therapy (ADT) for prostate cancer. I've heard that it may cause heart problems. Should I be worried? Johns Hopkins Med Lett Health After 50; 2010 May; 22(3):8. PubMed ID: 20518140 [No Abstract] [Full Text] [Related]
5. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537 [TBL] [Abstract][Full Text] [Related]
6. Cardiovascular risk during androgen deprivation therapy for prostate cancer. Jones TH BMJ; 2011 May; 342():d3105. PubMed ID: 21610041 [No Abstract] [Full Text] [Related]
7. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Saigal CS; Gore JL; Krupski TL; Hanley J; Schonlau M; Litwin MS; Cancer; 2007 Oct; 110(7):1493-500. PubMed ID: 17657815 [TBL] [Abstract][Full Text] [Related]
8. Long term androgen deprivation therapy in prostate cancer. Ockrim JL; Abel PD BMJ; 2008 Sep; 337():a1361. PubMed ID: 18809586 [No Abstract] [Full Text] [Related]
9. Cardiovascular and metabolic complications during androgen deprivation: exercise as a potential countermeasure. Galvão DA; Taaffe DR; Spry N; Joseph D; Newton RU Prostate Cancer Prostatic Dis; 2009; 12(3):233-40. PubMed ID: 19488067 [TBL] [Abstract][Full Text] [Related]
10. Competing risks for patients with localized prostate cancer. Seidenfeld J; Samson DJ; Albertsen PC J Natl Cancer Inst; 2007 Oct; 99(20):1498-9. PubMed ID: 17925533 [No Abstract] [Full Text] [Related]
13. The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy. Conteduca V; Di Lorenzo G; Tartarone A; Aieta M Crit Rev Oncol Hematol; 2013 Apr; 86(1):42-51. PubMed ID: 23092636 [TBL] [Abstract][Full Text] [Related]